β肾上腺素受体阻滞剂的研究进展  

Evolution of Research in β-adrenergic Receptor Blockers

作　　者：冷晓宁[1] 贾静[1] 张伟华[1] 

机构地区：[1]哈尔滨医科大学,黑龙江哈尔滨150001

出　　处：《心血管病学进展》2011年第4期569-572,共4页Advances in Cardiovascular Diseases

摘　　要：β受体阻滞剂广泛应用于心血管疾病和非心血管疾病的治疗,然而,该类药物的作用机制存在明显差异,且目前并没有完全阐释清楚。奈比洛尔是第三代β受体阻滞剂中的一种新药。它是该类药物中唯一的既具有心肌选择性,又能通过间接地产生一氧化氮使血管舒张的药物。现回顾β受体阻滞剂的发展,探讨目前已知的关于β受体阻滞剂的作用机制,评价该类药物并对它们在临床应用中的差异做基础研究。Beta-adrenergic receptor blockers are widely used in the treatment of cardiovascular and noncardiovascular diseases.However,their mechanism of action is not fully understood and differs among agents in this class.Nebivolol is one of the newer third-generation β-blockers.It is unique,as apart from its cardioselectivity,it also produces nitric oxide mediated vasodilation.This article explores known mechanisms for β-adrenergic receptor blockers,and evaluates them in terms of their clinical application.

关 键 词：Β肾上腺素受体阻滞剂 作用机制 奈比洛尔 高血压 心力衰竭 

分 类 号：R96[医药卫生—药理学]